PremierMaxCB-Platinum

Phase 1Biologic

UUniversity of Florida

PremierMaxCB-Platinum is one of 2 biologic programs targeting Joint. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

JointActive, not recruiting

JointPhase 1

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Joint

#DrugCompanyPhaseTrials

Chromium

FFayoum University

Phase 3

1 2

PremierMaxCB-Platinum

UUniversity of Florida

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1Active, not recruiting

Joint

NCT06415461

Clinical

Trials by Indication[1]

Joint1 trial

A Study Assessing the Safety of Cord Blood Product in Sacroiliac Joint Syndrome (SIJ)

Active, not recruiting·UUniversity of Florida·Phase 1·NCT06415461·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for PremierMaxCB-Platinum. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PremierMaxCB-Platinum compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PremierMaxCB-Platinum. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Florida

PremierMaxCB-Platinum

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Joint1 trial

References

Drug Info

Quick Facts

Related News